Literature DB >> 10488968

Effect of glycemic control on plasma plant sterol levels and post-heparin diamine oxidase activity in type 1 diabetic patients.

H Kojima1, H Hidaka, K Matsumura, Y Fujita, S Yamada, M Haneda, H Yasuda, R Kikkawa, A Kashiwagi.   

Abstract

We examined the effect of glycemic control on the plasma plant sterol levels (a measure of cholesterol absorption efficacy) and the plasma post-heparin diamine oxidase (DAO) activity (a measure of intestinal mucosal mass) in type 1 diabetes. The plasma plant sterol levels (mmol/mol of cholesterol) and the DAO activities after 30 U/kg of intravenous heparin were determined in age- and sex-matched three groups (12 type 1 diabetic patients undergoing conventional insulin therapy, ten patients undergoing intensive insulin therapy, and ten normal subjects). All patients continued their indicated insulin regimen for 14 days with a weight-maintaining energy restricted diet. The conventional group showed a significant higher (p < 0.001) level of the fasting plasma glucose (FPG) or the glycated albumin (GA), a higher (P < 0.01) DAO activity (2-fold of the peak level), which was observed 10-30 min after the heparin injection, and a higher (P < 0.01) plasma plant sterol levels (1.5-fold) compared with those in the other two groups, respectively. The DAO activity 30 min after the heparin injection significantly correlated with either the glycated albumin (GA) concentration or the plant sterol levels in all subjects. Furthermore, the acute glycemic control by the changes of insulin regimen from conventional to intensive showed a significant reduction of the DAO activity and plant sterols in the same patients. These results suggest that glycemic control in part relates to the intestinal adaptation to cholesterol absorption efficacy in type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10488968     DOI: 10.1016/s0021-9150(99)00070-2

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

1.  Type 1 diabetes is associated with an increase in cholesterol absorption markers but a decrease in cholesterol synthesis markers in a young adult population.

Authors:  Ivana Semova; Amy E Levenson; Joanna Krawczyk; Kevin Bullock; Kathryn A Williams; R Paul Wadwa; Amy S Shah; Philip R Khoury; Thomas R Kimball; Elaine M Urbina; Sarah D de Ferranti; Franziska K Bishop; David M Maahs; Lawrence M Dolan; Clary B Clish; Sudha B Biddinger
Journal:  J Clin Lipidol       Date:  2019-09-25       Impact factor: 4.766

2.  Do plant sterol concentrations correlate with coronary artery disease in type 1 diabetes? A report from the Pittsburgh Epidemiology of Diabetes Complications Study.

Authors:  Christina Marie Shay; Rhobert Wyn Evans; Trevor John Orchard
Journal:  J Diabetes       Date:  2009-06       Impact factor: 4.006

3.  Insulin Prevents Hypercholesterolemia by Suppressing 12α-Hydroxylated Bile Acids.

Authors:  Ivana Semova; Amy E Levenson; Joanna Krawczyk; Kevin Bullock; Mary E Gearing; Alisha V Ling; Kathryn A Williams; Ji Miao; Stuart S Adamson; Dong-Ju Shin; Satyapal Chahar; Mark J Graham; Rosanne M Crooke; Lee R Hagey; David Vicent; Sarah D de Ferranti; Srividya Kidambi; Clary B Clish; Sudha B Biddinger
Journal:  Circulation       Date:  2022-02-23       Impact factor: 39.918

4.  Markers of cholesterol synthesis are elevated in adolescents and young adults with type 2 diabetes.

Authors:  Ivana Semova; Amy E Levenson; Joanna Krawczyk; Kevin Bullock; Kathryn A Williams; R Paul Wadwa; Philip R Khoury; Thomas R Kimball; Elaine M Urbina; Sarah D de Ferranti; David M Maahs; Lawrence M Dolan; Amy S Shah; Clary B Clish; Sudha B Biddinger
Journal:  Pediatr Diabetes       Date:  2020-09-15       Impact factor: 4.866

5.  Down-regulation of hepatic and intestinal Abcg5 and Abcg8 expression associated with altered sterol fluxes in rats with streptozotocin-induced diabetes.

Authors:  V W Bloks; W M Bakker-Van Waarde; H J Verkade; I P Kema; H Wolters; E Vink; A K Groen; F Kuipers
Journal:  Diabetologia       Date:  2003-11-14       Impact factor: 10.122

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.